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We examined the dose responsiveness of polyarginine R18 (100, 300, and 1000 nmol/kg) when administered 60 minutes after
permanent middle cerebral artery occlusion (MCAO). The TAT-NR2B9c peptide, which is known to be neuroprotective in rodent
and nonhuman primate strokemodels, served as a positive control. At 24 hours afterMCAO, there was reduced total infarct volume
in R18 treated animals at all doses, but this reduction only reached statistical significance at doses of 100 and 1000 nmol/kg. The
TAT-NR2B9c peptide reduced infarct volume at doses of 300 and 1000 nmol/kg, but not to a statistically significant extent, while
the 100 nmol/kg dose was ineffective.The reduction in infarct volume with R18 and TAT-NR2B9c peptide treatments was mirrored
by improvements in one or more functional outcomes (namely, neurological score, adhesive tape removal, and rota-rod), but not
to a statistically significant extent. These findings further confirm the neuroprotective properties of polyarginine peptides and for
R18 extend its therapeutic time window and dose range, as well as demonstrating its greater efficacy compared to TAT-NR2B9c in
a severe stroke model. The superior neuroprotective efficacy of R18 over TAT-NR2B9c highlights the potential of this polyarginine
peptide as a lead candidate for studies in human stroke.
1. Introduction
While the incidence of stroke is falling in developed coun-
tries, it remains a leading cause of death and disability
worldwide, with an increasing global disease burden due to
an aging population, as well as the ongoing epidemics of
diabetes, hypertension, and obesity [1]. In terms of acute
therapies, for ischaemic stroke, reperfusion therapy using
tPA (tissue plasminogen activator) alone or more recently in
combination with thrombectomy is by far the most effective
treatment intervention currently available [2–6]. However,
despite the success of tPA/thrombectomy therapy, the num-
ber of stroke patients that receive this treatment is relatively
small. This is due to a combination of factors including
the narrow therapeutic time window for tPA/thrombectomy
(3–4.5 h after stroke), delays in patients obtaining medical
care, the requirement for a brain scan to exclude haemor-
ragic stroke, and the need for highly trained personnel and
specialised equipment to perform the intervention. Given
these limitations, the search continues for a neuroprotective
agent that can be safely administered early after stroke
onset to limit the extent of brain injury after stroke and
that can be used when reperfusion interventions cannot be
implemented. Additionally, any neuroprotective treatment
that improves the efficacy, safety, and therapeutic window for
tPA/thrombectomy would be of great clinical significance.
In terms of neuroprotective agents, our laboratory has
recently demonstrated that polyarginine and arginine-rich
peptides have potent neuroprotective properties in in vitro
injury models that mimic the effects of stroke [7–9]. More-
over, we have extended these in vitro findings by demon-
strating that the polyarginine peptides R9, R12, and R18
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significantly reduce infarct volume in a permanent middle
cerebral artery occlusion (MCAO) stroke model [8, 10].
Based on these in vitro and in vivo findings, we have
recently proposed [8, 9] that arginine-rich peptides including
“neuroprotective peptides” fused to arginine-rich cell pene-
trating peptides (e.g., TAT-NR2B9c [11] andTAT-JNKI-1 [12])
represent a new class of neuroprotective agents for which
arginine residues are critical for neuroprotection.
In the present study, we further evaluate the efficacy of
the R18 polyarginine peptide by examining its dose respon-
siveness and by extending the treatment administration time
from 30 minutes to 60 minutes after permanent MCAO.
In parallel, the study compares the efficacy of R18 with
that of TAT fused NR2B9c peptide (TAT-NR2B9c), which
has previously been demonstrated to be neuroprotective
in various rodent and nonhuman primate stroke models
and to reduce ischaemic brain lesions in humans following
endovascular repair of ruptured aneurysms [11, 13–15].
2. Materials and Methods
2.1. Peptides Used in the Study. The R18 (H-
RRRRRRRRRRRRRRRRRR-OH) and TAT-NR2B9c (H-
YRKKRRQRRR-KLSSIESDV-OH, also known as NA-1)
peptides used in the study were synthesised by Mimotopes
(Melbourne, Australia). The peptides were HPLC-purified to
98% purity and were subject to peptide hydrolysis and amino
acid liquid chromatography analysis to obtain a precise
measurement of peptide content (Mimotopes). The peptides
were prepared in 0.9% sodium chloride for injection (Pfizer,
Perth, Australia), aliquoted into a 650 𝜇L volume in a 3mL
syringe and stored at −20∘C until use.
2.2. Surgical Procedure for Permanent Middle Cerebral Artery
Occlusion. The surgical procedures for permanent middle
cerebral artery occlusion (MCAO) as well as behavioural
and histologic assessment were performed in accordance
with the Animal Ethics Committee of the University of
Western Australia and following the guidelines outlined by
the Australian Code for the Care and Use of Animals for
Scientific Purposes.
The filament permanent MCAO stroke model as per-
formed in our laboratory has been described previously [10,
16]. Briefly, male Sprague-Dawley rats weighing 275–340 g
that had been fasted overnight underwent facemask anes-
thesia with 4% of isoflurane (mix 30% oxygen/70% nitrous
oxide) and maintenance with 2% isoflurane. The tail artery
was cannulated to allow blood pressure monitoring and for
measurement of arterial blood gases (pO
2
, pCO
2
), pH, and
glucose. The MCAO procedure was considered successful if
there was a >25% decrease from baseline in cerebral blood
flow after insertion of the filament, as measured by laser
Doppler flowmetry. During surgery, body temperature was
closely monitored using a rectal probe (Physitemp Instru-
ments, Clifton, USA) and maintained at 37–37.8∘C, with fan
heating or cooling, as required.
At sixty minutes after MCAO rats were treated intra-
venously through the right internal jugular vein using an
infusion pump with the vehicle (0.9% sodium chloride,
600𝜇L over 6min) orwith three different doses of the peptide
(R18 or TAT-NR2B9c: 100, 300, or 1000 nmol/kg, 600𝜇L over
6min). Treatments were randomised and all procedures were
performed while being blinded to treatments.
Fifty male Sprague-Dawley rats underwent surgery for
permanent MCAO. Eight animals were excluded from the
study: five animals were excluded due to an insufficient
decrease in cerebral blood flow following MCAO, one was
excluded due to death during anesthetic induction, and two
animals were excluded because no obvious infarct lesion
was detected 24 hours after MCAO (one saline and one R18
100 nmol/kg treated animal). A further six animals died sev-
eral hours before the 24-hour post-MCAO study end-point
but were still included in the final infarct volume analysis.
These animals comprised two R18 treated (one 100 nmol/kg
and one 1000 nmol/kg) and four TAT-NR2B9c treated (two
100 nmol/kg, one 300 nmol/kg, and one 1000 nmol/kg) ani-
mals. While the exact cause of the deaths could not be
determined, it is possible that it reflects the severity of the
stroke in this model, which is known to result in up to 90%
of the affected hemisphere being infarcted by the stroke. For
infarct volume analysis each treatment group consisted of
six animals. Due to animal deaths before the 24-hour study
end-point, four to six animals per group were available for
behavioural testing.
2.3. Postsurgical Monitoring. The body temperature of ani-
mals was measured every 30–60 minutes using a rectal probe
for at least 2 hours after surgery andmaintained between 37.0
and 37.8∘C. To avoid hypothermia, rat cages were placed on a
heating mat during the postsurgical monitoring and housed
in a holding room maintained at 26–28∘C. If necessary,
additional heating or cooling was performed by applying fan
heating or a cold water spray.
2.4. Infarct Volume Assessment. Infarct volume was assessed
24 hours after MCAO as previously described [17]. Briefly
2mm cerebral coronal brain slices were stained in 3% 2,3,5-
triphenyltetrazolium chloride (Sigma-Aldrich, St. Louis,
USA). Digital images of coronal brain slices were acquired
and analysed using ImageJ software (3rd edition, NIH,
Bethesda, USA) by an operator blind to treatment status.The
total infarct volume was determined by measuring the areas
of infarcted tissue on both sides of the 2mm sections and
corrected for cerebral oedema [17].
2.5. Behavioural Testing. In order to assess if any treatment
improved sensorimotor outcomes, three behavioural tests
were performed 24 hours after MCAO. A neurological
assessment was performed using a five-point scale (0−5)
developed by Bederson et al. [18]. Scores range between 0
for no deficits, 1 for flexed forepaw, 2 for inability to resist
lateral push, 3 for circling, 4 for agitated circling, and 5 for
unresponsiveness to stimulation/stupor. The adhesive tape
removal test is a bilateral asymmetry paw test to assess
sensorimotor impairment [19]. Adhesive tape (Diversified
Biotech, Dedham, USA) 10mm × 10mm in size was placed
on the palmar surface of the forepaw and the time taken for
the first attempt to remove tape (time to detect tape), the
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Table 1: Physiological parameters (mean ± SD).
Parameter
Experimental groups
Vehicle (saline) R18 (nmol/kg) TAT-NR2B9c (nmol/kg)
100 300 1000 100 300 1000
PaO
2
, before MCAO 117.19 ± 22.44 114.66 ± 11.34 115.16 ± 13.79 124.16 ± 14.35 109.33 ± 9.04 117.83 ± 16.55 112.83 ± 12.93
PaCO
2
, before MCAO 38.33 ± 2.94 39 ± 3.57 39.5 ± 3.50 42.68 ± 6.17 43.66 ± 8.93 39.5 ± 5.78 39.83 ± 3.74
pH, before MCAO 7.36 ± 0.05 7.42 ± 0.09 7.37 ± 0.04 7.44 ± 0.06 7.38 ± 0.04 7.45 ± 0.04 7.39 ± 0.06
Glucose (mmol/L), before
MCAO 8.0 ± 1.37 8.15 ± 0.68 7.81 ± 0.96 8.11 ± 1.00 7.21 ± 1.31 7.71 ± 0.81 7.50 ± 1.73
BP (mmHg), average during
surgery 87.33 ± 4.17 88.33 ± 7.06 84 ± 5.13 91.6 ± 5.44 91 ± 3.09 83.66 ± 6.34 88 ± 3.68
Temperature (∘C), average 2 h
after surgery 37.51 ± 0.16 37.37 ± 0.25 37.46 ± 0.29 37.46 ± 0.21 37.43 ± 0.25 37.53 ± 0.17 37.52 ± 0.21
time taken to remove the tape, and the number of attempts
to remove tape were recorded. Each forelimb was assessed
sequentially starting with the unaffected side (right side) with
animals having a maximum of 120 seconds to complete the
task (normal rats usually take between 5 and 30 sec to remove
the tape). Each rat was assessed three times on the day prior to
the surgery and once 24 hours after MCAO.The rota-rod test
assesses balance and coordination by assessing a rat’s ability
to keep walking on a rotating rod, with the speed of rotation
being progressively increased from 4 to 40 revolutions per
minute. The time the animal falls was recorded.
2.6. Statistical Analysis. Total infarct volume and physio-
logical parameters were evaluated by analysis of variance
(ANOVA) followed by Fisher’s post hoc analysis. The neu-
rological assessment measurements were analysed using
Kruskal-Wallis test. Data from adhesive tape removal and
rota-rod tests were analysed using ANOVA followed by
Scheffe´’s multiple comparison post hoc analysis. 𝑃 < 0.05
was considered as significant. Data are presented as mean ±
standard deviation (SD).
3. Results
3.1. Physiological Data, Infarct Volume Measurements, and
Animal Deaths. Physiological parameters measured during
surgery and beforeMCAOwere within the normal range and
did not differ significantly between animal treatment groups
(Table 1).
Data on themean total infarct volumes for each treatment
group are presented in Figure 1. These results show that the
R18 peptide significantly reduced infarct volume at doses of
100 nmol/kg and 1000 nmol/kg by 19.7% (𝑃 = 0.043) and 24%
(𝑃 = 0.013), respectively, while, at the 300 nmol/kg, infarct
volume was reduced by 12% (𝑃 = 0.19), albeit not to a statis-
tically significant extent. By contrast, while the TAT-NR2B9c
peptide at doses of 300 nmol/kg and 1000 nmol/kg reduced
infarct volume by 6.8% (𝑃 = 0.56) and 7% (𝑃 = 0.55),
respectively, these effects were not statistically significant.
At 100 nmol/kg, TAT-NR2B9c was ineffective in reducing
infarct volume. In comparative terms, at 100 nmol/kg R18 was
significantly more effective in reducing infarct volume than
TAT-NR2B9c (19.7% versus 1.1%, 𝑃 = 0.045).
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Figure 1: Infarct volume measurements 24 hours after permanent
MCAO. Treatments were administered intravenously (saline vehicle
or R18 and TAT-NR2B9c peptide at 100, 300, or 1000 nmol/kg;
600 𝜇L volume over 6min) 60 minutes after MCAO. Values are
mean ± SD. ∗𝑃 < 0.05 when compared to the vehicle control group
and #𝑃 < 0.05 when compared to the TAT-NR2B9c 100 nmol/kg
group. † denotes animals that died several hours before the 24-hour
post-MCAO study end-point but were still included in the final
infarct volume analysis.
3.2. Functional Outcome Assessment. Although not statisti-
cally significant, there was a trend towards improvement in
the performance in some of the behavioural parameters mea-
sured for R18 and TAT-NR2B9c treatment groups (Figures
2–4). Neurological scores for 100, 300, and 1000 nmol/kg
R18 treatment animals showed improved outcomes compared
with the vehicle-treated controls (Figure 2). By contrast,
for TAT-NR2B9c, only the 1000 nmol/kg treatment group
was associated with an improvement in neurological score
compared to vehicle. Measurements for the adhesive tape
test after MCAO were variable; however, treatment with the
300 nmol/kg R18 or 1000 nmol/kg TAT-NR2B9c appeared
to improve the time required to detect tape from the right
paw of the nonaffected forelimb, while the 100 nmol/kg TAT-
NR2B9c treatment appeared to improve the time required
to detect tape from the left paw (Figure 3(a)). Similarly, the
number of attempts required to remove the tape from the
right and left paw was increased in animals treated with
1000 nmol/kg and 100 nmol/kg TAT-NR2B9c, respectively
(Figure 3(b)). Additionally, treatment with 1000 nmol/kg R18
was associated with the shortest time to remove tape from
the right paw (Figure 3(c)). For the rota-rod test, the group
receiving 100 nmol/kg R18 was the only treatment group
4 Stroke Research and Treatment
N
eu
ro
lo
gi
ca
l g
ra
di
ng
Vehicle 100 300 1000 100 300 1000
R18 TAT-NR2B9c
0
1
2
3
4
5
sc
or
e
Figure 2: Neurological grading scores 24 hours after permanent
MCAO (0 = no deficit, 5 = major deficit) for saline (vehicle)
and peptide (R18 and TAT-NR2B9c at 100, 300, or 1000 nmol/kg)
treatment groups. Lines on graph indicate range and median for
neurological scores.
that displayed an increased time to remain on the rotating
cylinder when compared to vehicle (118 sec versus 77 sec,
Figure 4).
3.3. Weight Loss Measurement. All groups recorded a loss in
body weight 24 hours after MCAO ranging from 28.5 grams
for the TAT-NR2B9c 100 nmol/kg treatment group to ≈34.5 g
for the 300 nmol/kg R18 and TAT-NR2B9c treatment groups
(Figure 5).
4. Discussion
The results of the present study add to our previous findings,
which showed that 1000 nmol/kg R18 when administered 30
minutes after permanent MCAO significantly reduces infarct
volume in the rat [10]. Importantly, we now show that R18 is
effective over an evenwider therapeuticwindow (60min) and
broader dose range (100–1000 nmol/kg) and that, on balance,
R18 is more effective than the extensively characterised
neuroprotective peptide, TAT-NR2B9c. Treatment with R18,
as well as to a lesser extent TAT-NR2B9c, resulted in some
functional recovery as assessed by behavioural tests, but not
to statistically significant levels, which most likely reflects the
severity of the stroke model used coupled with the relatively
small numbers of animals in the study. Notwithstanding
these limitations, our findings highlight the potential clinical
applicability of R18 as a therapeutic intervention in stroke,
especially in light of evidence that it is superior as a neuro-
protective agent to TAT-NR2B9c, which is planned to enter
a phase 3 clinical trial in stroke patients [20]. The superior
neuroprotective efficacy of R18 compared to TAT-NR2B9c
is consistent with our in vitro findings in a glutamic acid
induced neuronal excitotoxicity model of cell death [8].
The TAT-NR2B9c peptide has been shown to be neu-
roprotective in rodent [11, 21–25] and nonhuman primate
stroke models [13, 14] and has been found to be safe and
cause a nonsignificant reduction in ischaemic brain lesions
in patients undergoing aneurysm surgery [15]. The NR2B9c
peptide (KLSSIESDV) is derived from the intracellular ter-
minal carboxyl region of theN-methyl-D-aspartate (NMDA)
receptor NR2B subunit protein [11] and is fused to the
arginine-rich TAT peptide (YRKKRRQRRR) to allow entry
into the brain and neuronal cells. The NR2B9c peptide was
designed to act as a competitive inhibitor of the PSD-95
adaptor protein (postsynaptic density-95) binding to the
NR2B subunit protein and, in doing so, to block downstream
cell signaling associated with overstimulation of the NMDA
receptor, leading to nitric oxide synthase activation and
subsequent production of nitric oxide; however, we [9]
and others [25, 26] have proposed other mechanisms for
neuroprotection.
As an alternative mechanism, we have proposed that
the neuroprotective properties of TAT-NR2B9c are largely
mediated by the TAT peptide itself [9], which we [7, 27] and
others [28, 29] have previously reported to display modest
neuroprotective properties. Furthermore, due to the TAT
peptide’s arginine content and positive charge, it is likely
to possess a similar mode of action as polyarginine and
arginine-rich peptides [8, 9]. For arginine-rich peptides, we
have previously hypothesised that at least in part neuropro-
tection is related to the ability of these peptides to transverse
cell membranes and, in doing so, decrease the levels of cell
surface ion channels and receptors, thereby reducing the toxic
influx of calcium that occurs in neurons following cerebral
ischaemia [8, 9]. This mechanism of action is in line with
the confirmed ability of arginine-rich peptides to reduce
glutamate excitotoxic calcium influx in cortical neurons [8,
9, 30–32] and evoke receptor currents in NR1-NR2 NMDA
receptor-expressing oocytes [33], as well as the observation
that peptide neuroprotective efficacy correlates with peptide
endocytic or cell membrane transversing properties [34].
In addition, several studies have demonstrated that TAT
fused peptides and arginine-rich cell penetrating peptides
can reduce the expression of cell surface ion channels and
receptors in neurons [26, 31, 35–38] and other cells [39].
There is evidence to indicate that arginine residues
are critical elements for peptide and protein mitochondrial
uptake [40–43] and that arginine-rich peptides exert bene-
ficial effects on mitochondria. For example, in isolated rat
liver mitochondria, cationic tetra- and polycationic peptides
and especially those containing arginine were highly effective
in blocking calcium induced mitochondrial swelling and
in maintaining membrane potential [44]. Similarly, cationic
compounds including tetrapeptides containing an arginine
residue (e.g., SS-20, SS-31) or biguanidines (e.g., metformin)
have been shown to target mitochondria and exert positive
effects on the organelle by limiting complex I activity and
reactive oxygen species production [41, 45], inhibiting the
opening of the mitochondrial permeability transition pore
[46], protecting cristae architecture [47], accelerating ATP
recovery [47], and preventing cytochrome c release [48].
While the exact mechanisms for these beneficial effects on
mitochondria are not fully known, the ability of cationic
guanidino groups to interact with anionic phosphate groups
of mitochondrial membrane phospholipids especially the
inner membrane phospholipid cardiolipin (−2 net charge)
may be a contributing factor.
Recently, Marshall et al. [49] confirmed the neuropro-
tective properties of polyarginine peptides in an in vivo
NMDA-induced retinal ganglion cell excitotoxicity model
and provided evidence that the peptides reduce neuronal
mitochondrial oxidative stress. Furthermore, it was demon-
strated in HEK293 cells that polyarginine peptides localise to
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Figure 3: Functional assessment measurements using adhesive tape removal test before and 24 hours after MCAO for saline (vehicle) and
peptide (R18 and TAT-NR2B9c at 100, 300, or 1000 nmol/kg) treatment groups. (a) Time to detect tape. (b) Number of attempts to remove
tape. (c) Time to remove tape. Values are mean ± SD. Maximum time allowed for adhesive tape removal was 120 seconds.
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Figure 4: Rota-rod performance 24 hours after permanent MCAO
for saline (vehicle) and peptide (R18 and TAT-NR2B9c at 100, 300,
or 1000 nmol/kg) treatment groups. Values are mean ± SD.
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Figure 5: Weight loss at 24 hours after permanent MCAO for
saline (vehicle) and peptide (R18 and TAT-NR2B9c at 100, 300, or
1000 nmol/kg) treatment groups. Values are mean ± SD.
mitochondria and reduce mitochondrial respiration, mem-
brane potential, and levels of reactive oxygen species [49].
It is also interesting to note that Marshall et al. [49] found
that polyarginine peptides taken up by retinal ganglion cells
are localised within small spherical cytoplasmic structures,
which the authors suggested to be mitochondria. Also of
interest are recent studies surrounding the arginine-rich
Borna disease viral mitochondrial-targeting protein, X. The
full-length protein X and X-derived peptide fused to a cell
penetrating peptide display neuronal, axonal, and mitochon-
drial protective properties [50, 51].
Another mechanism whereby arginine-rich peptides
exert a neuroprotective effect may be related to the ability
of polyarginine and arginine-rich peptides to inhibit the
proteolytic activity of proprotein convertases (e.g., furin and
PC4 [52, 53]), cathepsin C [54], and the proteasome [55, 56],
an effect thatmay be beneficial following brain ischaemia. For
example, furin is ubiquitously expressed calcium-dependent
convertase responsible for the activation ofmembrane bound
proteins, including metalloproteinases, which are known to
have adverse effects on the blood brain barrier following
stroke [57]. Similarly, treatments known to inhibit the protea-
some which is responsible for the degradation of short-lived
cytosolic proteins are known to reduce brain injury in stroke
[58, 59].
Taken together, the results from the current study support
other findings from our laboratory [8–10] and suggest that
polyarginine and arginine-rich peptides may represent a
new class of neuroprotective agents with enormous clinical
potential for the treatment of acute and chronic neurological
injuries. Importantly, it is possible that the reported beneficial
effects of arginine-rich cell penetrating peptides fused to a
“neuroprotective peptide” in animal studies of acute brain
injury are largely attributable to the effects of the arginine
residues contained within the peptide [9]. This adds to the
growing weight of evidence suggesting that arginine-rich
peptides (including R18) may be beneficial in a range of
acute clinical neurological disorders. There is also evidence
that arginine-rich peptides may improve functional recovery
from central nervous system injury as evidenced by exper-
imental studies on the effects of TAT-NR2B9c in stroke [60]
and TAT-ISP in spinal cord injury [61]. Consequently, there is
a growing body of evidence that supports the need for clinical
studies on the effects of arginine-rich peptides to establish
whether these peptides are equally beneficial in patients with
stroke or other acute and chronic neurological disorders.
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